Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Barros, Carlos C ^a   Haro, Anderson ^a   Russo, Fernanda J V P ^a   Schadock, Ines ^b   Almeida, Sandro S ^a   Ribeiro, Rosane A ^c   Vanzela, Emerielle C ^c   Lanzoni, Valeria P ^a   Barros, Flavio C ^d   Moraes, Milton R ^a   Mori, Marcelo A ^a   Bacurau, Reury F P ^e   Wurtele, Martin ^a   Boschero, Antônio C ^c   Carneiro, Everardo M ^c   Bader, Michael ^b   Pesquero, Joao B ^a   Araujo, Ronaldo C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d PAULISTA UNIVERSITY   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; C PEPTIDE; GLUCOSE; LEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE; GENE EXPRESSION; GENE INACTIVATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEPATOMEGALY; INSULIN RELEASE; KALLIKREIN KININ SYSTEM; KININ B1 RECEPTOR GENE; KININ B2 RECEPTOR GENE; LIPID METABOLISM; LIVER FUNCTION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PROTEIN BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; GLUCOSE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; KALLIKREIN-KININ SYSTEM; LIVER; MICE; MICE, KNOCKOUT; MICE, OBESE; PHOSPHORYLATION; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

ANIMALIA; MUS;

EID: 84864052492     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040573     Document Type: Article

References (49)

1. Popkin BM, (2002) The shift in stages of the nutrition transition in the developing world differs from past experiences! Public Health Nutr 5: 205-214.
2. Lenz M, Richter T, Muhlhauser I, (2009) The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int 106: 641-648.
3. Ginsberg HN, Maccallum PR, (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. J Clin Hypertens (Greenwich) 11: 520-527.
4. Kahn SE, Hull RL, Utzschneider KM, (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
5. Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, et al. (2009) Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. Proc Natl Acad Sci U S A 106: 12121-12126.
6. Utzschneider KM, Kahn SE, (2006) Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91: 4753-4761.
7. Lattuada G, Ragogna F, Perseghin G, (2011) Why does NAFLD predict type 2 diabetes? Curr Diab Rep 11: 167-172.
8. Smith BW, Adams LA, (2011) Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7: 456-465.
9. Pesquero JB, Bader M, (1998) Molecular biology of the kallikrein-kinin system: from structure to function. Braz J Med Biol Res 31: 1197-1203.
10. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, et al. (2005) The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99: 6-38.
11. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, et al. (2001) Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 38: 1355-1360.
12. Tschope C, Westermann D, (2008) Development of diabetic cardiomyopathy and the kallikrein-kinin system-new insights from B1 and B2 receptor signaling. Biol Chem 389: 707-711.
13. Kishi K, Muromoto N, Nakaya Y, Miyata I, Hagi A, et al. (1998) Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47: 550-558.
14. Mori MA, Araujo RC, Reis FC, Sgai DG, Fonseca RG, et al. (2008) Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 57: 1491-1500.
15. Araujo RC, Mori MA, Merino VF, Bascands JL, Schanstra JP, et al. (2006) Role of the kinin B1 receptor in insulin homeostasis and pancreatic islet function. Biol Chem 387: 431-436.
16. Lindstrom P, (2007) The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal 7: 666-685.
17. Polonsky KS, Rubenstein AH, (1984) C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33: 486-494.
18. Li T, Ma H, Park YJ, Lee YK, Strom S, et al. (2009) Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase in human hepatocytes and in high fat diet-fed mice. Biochim Biophys Acta 1791: 991-996.
19. Miyata T, Taguchi T, Uehara M, Isami S, Kishikawa H, et al. (1998) Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 138: 344-352.
20. Isami S, Kishikawa H, Araki E, Uehara M, Kaneko K, et al. (1996) Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 39: 412-420.
21. Beard KM, Lu H, Ho K, Fantus IG, (2006) Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthase-mediated inhibition of Jun NH2-terminal kinase. Diabetes 55: 2678-2687.
22. Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G, (2003) Insulin clearance in obesity. J Am Coll Nutr 22: 487-493.
23. Sato H, Terasaki T, Mizuguchi H, Okumura K, Tsuji A, (1991) Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. Diabetologia 34: 613-621.
24. Duckworth WC, Hamel FG, Peavy DE, (1988) Hepatic metabolism of insulin. Am J Med 85: 71-76.
25. Carlsson PO, Andersson A, Jansson L, (1998) Influence of age, hyperglycemia, leptin, and NPY on islet blood flow in obese-hyperglycemic mice. Am J Physiol 275: E594-601.
26. Westman S, (1968) Development of the obese-hyperglycaemic syndrome in mice. Diabetologia 4: 141-149.
27. Phillips J, Phillips PJ, (2009) Children get type 2 diabetes too. Aust Fam Physician 38: 699-703.
28. Han JC, Lawlor DA, Kimm SY, (2010) Childhood obesity. Lancet 375: 1737-1748.
29. Al Mamun A, Cramb SM, O'Callaghan MJ, Williams GM, Najman JM, (2009) Childhood overweight status predicts diabetes at age 21 years: a follow-up study. Obesity (Silver Spring) 17: 1255-1261.
30. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ, (1997) Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46: 1950-1957.
31. Adam A, Leclair P, Montpas N, Koumbadinga GA, Bachelard H, et al. (2010) Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases. Neuropeptides 44: 69-75.
32. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, et al. (2002) ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40: 329-334.
33. Cheng Z, White MF, (2011) Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 14: 649-661.
34. Soyal S, Krempler F, Oberkofler H, Patsch W, (2006) PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 49: 1477-1488.
35. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, et al. (2010) Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A 107: 10190-10195.
36. Wang PH, Campanholle G, Cenedeze MA, Feitoza CQ, Goncalves GM, et al. (2008) Bradykinin [corrected] B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury. PLoS One 3: e3050.
37. Mulhall BP, Ong JP, Younossi ZM, (2002) Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17: 1136-1143.
38. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, et al. (2001) Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34: 288-297.
39. Potter JJ, Womack L, Mezey E, Anania FA, (1998) Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 244: 178-182.
40. Enriquez A, Leclercq I, Farrell GC, Robertson G, (1999) Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 255: 300-306.
41. Friedman JM, (2002) The function of leptin in nutrition, weight, and physiology. Nutr Rev 60: S1-14; discussion S68-84, 85-17.
42. Sancho-Bru P, Bataller R, Fernandez-Varo G, Moreno M, Ramalho LN, et al. (2007) Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology 133: 2019-2028.
43. Riad A, Zhuo JL, Schultheiss HP, Tschope C, (2007) The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr Opin Nephrol Hypertens 16: 22-26.
44. Pruneau D, Belichard P, Sahel JA, Combal JP, (2010) Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr Opin Investig Drugs 11: 507-514.
45. Barros CC, Almeida SS, Mori MA, Valero VB, Haro AS, et al. (2009) Efficient method for obtaining Lep(ob)/Lep(ob)-derived animal models using adipose tissue transplantations. Int J Obes (Lond) 33: 938-944.
46. Torsoni MA, Carvalheira JB, Pereira-Da-Silva M, de Carvalho-Filho MA, Saad MJ, et al. (2003) Molecular and functional resistance to insulin in hypothalamus of rats exposed to cold. Am J Physiol Endocrinol Metab 285: E216-223.
47. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
48. Bordin S, Boschero AC, Carneiro EM, Atwater I, (1995) Ionic mechanisms involved in the regulation of insulin secretion by muscarinic agonists. J Membr Biol 148: 177-184.
49. Castro CH, Shin CS, Stains JP, Cheng SL, Sheikh S, et al. (2004) Targeted expression of a dominant-negative N-cadherin in vivo delays peak bone mass and increases adipogenesis. J Cell Sci 117: 2853-2864.